Protocol for a phase 3 trial to evaluate the effectiveness and safety of a heterologous, two-dose vaccine for Ebola virus disease in the Democratic Republic of the Congo (2022)

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1136/bmjopen-2021-055596

PubMed Identifier: 35260458

Publication URI: http://europepmc.org/abstract/MED/35260458

Type: Journal Article/Review

Parent Publication: BMJ Open

Issue: 3

ISSN: 2044-6055